Neuhofstrasse 24
Baar 6340
Switzerland
41 435 020 580
https://www.polypeptide.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 1.273
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Klaus Peter Wilden | Executive Chair | 305,77k | N/D | 1957 |
Mr. Juan Jose Gonzalez | Chief Executive Officer | 1,17M | N/D | 1972 |
Mr. Marc Augustin | Chief Financial Officer | N/D | N/D | 1972 |
Mr. Jens Fricke | Director of Global Operations | N/D | N/D | 1965 |
Rene Vestergaard | Director of Corporate Finance | N/D | N/D | N/D |
Mr. Olivier Ludemann-Hombourger | Director Global Innovation & Technology | N/D | N/D | 1972 |
Ms. Christina Del Vecchio | General Counsel & Corporate Secretary | N/D | N/D | 1978 |
Ms. Monika Casanova | Chief Human Resources Officer | N/D | N/D | 1979 |
Christophe Chevalier | Head of Technical Department - Braine | N/D | N/D | N/D |
Krister Svard | Chief Information Security Officer & Global IT Services VC | N/D | N/D | N/D |
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
L'ISS Governance QualityScore di PolyPeptide Group AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.